FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306708432> ?p ?o ?g. }

• W4306708432 endingPage "115108" @default.
• W4306708432 startingPage "115108" @default.
• W4306708432 abstract "Chronic Myeloid Leukemia (CML) is a hematologic neoplasia, characterized as a proliferative disease of the hematopoietic system. Imatinib mesylate (IM), a selective tyrosine kinase inhibitor, is considered a first-line therapy for CML, indicated for both adult and pediatric patients presenting the Philadelphia chromosome (Ph+). However, patients in treatment with IM may show different responses due to interindividual pharmacokinetic variability. Therapeutic drug monitoring should be routinely performed to identify treatment response profile, adherence to treatment, or possible drug interactions, thus supporting better treatment management. Volumetric absorptive microsampling (VAMS) are innovative devices for blood collection whose advantages include the possibility of home collection by the patient or at the physician's office. The assay was fully validated according to bioanalytical validation guidelines. Estimated plasma concentrations of IM were not statistically different between groups according to adherence (p = 0.15), with median of 789 ng ml-1 in the group with some level of non-adherence versus 1141.9 ng ml-1 in the group with adherence, classified with the Morisky-Green questionnaire. This study included 33 patients with CML in treatment with IM. These patients answered socioeconomic, sociodemographic, and adherence profile (Morisky-Green) questionnaires. Patients also received instructions for home blood collection with VAMS devices. Afterwards, the samples were analyzed by LC-MS/MS. The mean age of the patients was 52 years, 84.8% were ingesting doses of 400 mg/day and the majority were male (69.7%). IM and its metabolite NIM were extracted from VAMS with an aqueous solution with 0.1% formic acid, followed by protein precipitation with acetonitrile. The methodology developed in this study was satisfactory for the determination of IM and NIM in VAMS and can be used in hospital and office routines for the therapeutic monitoring of patients with CML." @default.
• W4306708432 created "2022-10-19" @default.
• W4306708432 creator A5001950236 @default.
• W4306708432 creator A5005781604 @default.
• W4306708432 creator A5018253236 @default.
• W4306708432 creator A5050372090 @default.
• W4306708432 creator A5054240360 @default.
• W4306708432 creator A5055086899 @default.
• W4306708432 creator A5055267558 @default.
• W4306708432 creator A5058840924 @default.
• W4306708432 creator A5074110261 @default.
• W4306708432 creator A5081728952 @default.
• W4306708432 date "2023-01-01" @default.
• W4306708432 modified "2023-09-27" @default.
• W4306708432 title "Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia" @default.
• W4306708432 cites W1581887873 @default.
• W4306708432 cites W1989671297 @default.
• W4306708432 cites W1994327535 @default.
• W4306708432 cites W1999742105 @default.
• W4306708432 cites W2031756259 @default.
• W4306708432 cites W2034074778 @default.
• W4306708432 cites W2055515709 @default.
• W4306708432 cites W2068734383 @default.
• W4306708432 cites W2119227173 @default.
• W4306708432 cites W2133365230 @default.
• W4306708432 cites W2149330162 @default.
• W4306708432 cites W2153484612 @default.
• W4306708432 cites W2162139090 @default.
• W4306708432 cites W2372510539 @default.
• W4306708432 cites W2555973682 @default.
• W4306708432 cites W2612144746 @default.
• W4306708432 cites W2788900104 @default.
• W4306708432 cites W2796423005 @default.
• W4306708432 cites W2989771971 @default.
• W4306708432 cites W3202334351 @default.
• W4306708432 cites W3211251307 @default.
• W4306708432 cites W32471882 @default.
• W4306708432 cites W4282841608 @default.
• W4306708432 doi "https://doi.org/10.1016/j.jpba.2022.115108" @default.
• W4306708432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36279845" @default.
• W4306708432 hasPublicationYear "2023" @default.
• W4306708432 type Work @default.
• W4306708432 citedByCount "3" @default.
• W4306708432 countsByYear W43067084322023 @default.
• W4306708432 crossrefType "journal-article" @default.
• W4306708432 hasAuthorship W4306708432A5001950236 @default.
• W4306708432 hasAuthorship W4306708432A5005781604 @default.
• W4306708432 hasAuthorship W4306708432A5018253236 @default.
• W4306708432 hasAuthorship W4306708432A5050372090 @default.
• W4306708432 hasAuthorship W4306708432A5054240360 @default.
• W4306708432 hasAuthorship W4306708432A5055086899 @default.
• W4306708432 hasAuthorship W4306708432A5055267558 @default.
• W4306708432 hasAuthorship W4306708432A5058840924 @default.
• W4306708432 hasAuthorship W4306708432A5074110261 @default.
• W4306708432 hasAuthorship W4306708432A5081728952 @default.
• W4306708432 hasBestOaLocation W43067084321 @default.
• W4306708432 hasConcept C121608353 @default.
• W4306708432 hasConcept C126322002 @default.
• W4306708432 hasConcept C178790620 @default.
• W4306708432 hasConcept C185592680 @default.
• W4306708432 hasConcept C2776960273 @default.
• W4306708432 hasConcept C2777583451 @default.
• W4306708432 hasConcept C2778461978 @default.
• W4306708432 hasConcept C2778729363 @default.
• W4306708432 hasConcept C2778820342 @default.
• W4306708432 hasConcept C2780194963 @default.
• W4306708432 hasConcept C3019892230 @default.
• W4306708432 hasConcept C43617362 @default.
• W4306708432 hasConcept C71924100 @default.
• W4306708432 hasConcept C72092618 @default.
• W4306708432 hasConcept C90924648 @default.
• W4306708432 hasConcept C98274493 @default.
• W4306708432 hasConceptScore W4306708432C121608353 @default.
• W4306708432 hasConceptScore W4306708432C126322002 @default.
• W4306708432 hasConceptScore W4306708432C178790620 @default.
• W4306708432 hasConceptScore W4306708432C185592680 @default.
• W4306708432 hasConceptScore W4306708432C2776960273 @default.
• W4306708432 hasConceptScore W4306708432C2777583451 @default.
• W4306708432 hasConceptScore W4306708432C2778461978 @default.
• W4306708432 hasConceptScore W4306708432C2778729363 @default.
• W4306708432 hasConceptScore W4306708432C2778820342 @default.
• W4306708432 hasConceptScore W4306708432C2780194963 @default.
• W4306708432 hasConceptScore W4306708432C3019892230 @default.
• W4306708432 hasConceptScore W4306708432C43617362 @default.
• W4306708432 hasConceptScore W4306708432C71924100 @default.
• W4306708432 hasConceptScore W4306708432C72092618 @default.
• W4306708432 hasConceptScore W4306708432C90924648 @default.
• W4306708432 hasConceptScore W4306708432C98274493 @default.
• W4306708432 hasFunder F4320322025 @default.
• W4306708432 hasFunder F4320322502 @default.
• W4306708432 hasLocation W43067084321 @default.
• W4306708432 hasLocation W43067084322 @default.
• W4306708432 hasOpenAccess W4306708432 @default.
• W4306708432 hasPrimaryLocation W43067084321 @default.
• W4306708432 hasRelatedWork W1980928536 @default.
• W4306708432 hasRelatedWork W2013094135 @default.
• W4306708432 hasRelatedWork W2105138820 @default.
• W4306708432 hasRelatedWork W2139383007 @default.

• next